scholarly journals Initial management strategies for follicular lymphoma

2012 ◽  
Vol 1 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Qiushi Chen ◽  
Turgay Ayer ◽  
Loretta J Nastoupil ◽  
Miray Seward ◽  
Hongzheng Zhang ◽  
...  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dalal Al Hasan ◽  
Ameen Yaseen ◽  
Mohammad Al Roudan ◽  
Lee Wallis

Abstract Background The objective of this study was to describe the epidemiology of severe hypoglycaemia in Kuwait, aiming to provide a preliminary background to update the current guidelines and improve patient management. Method This was a prospective analysis of severe hypoglycaemia cases retrieved from emergency medical services (EMS) archived data between 1 January and 30 June 2020. The severe hypoglycaemia cases were then sub-grouped based on EMS personal initial management and compared in terms of scene time, transportation rate, complications and outcomes. The primary outcomes were GCS within 10–30 min and normal random blood glucose (RBS) within 10–30 min. Results A total of 167 cases met the inclusion criteria. The incidence of severe hypoglycaemia in the national EMS was 11 per 100,000. Intramuscular glucagon was used on scene in 89% of the hypoglycaemic events. Most of the severe hypoglycaemia patients regained normal GCS on scene (76.5%). When we compared the two scene management strategies for severe hypoglycaemia cases, parenteral glucose administration prolonged the on-scene time (P = .002) but was associated with more favourable scene outcomes than intramuscular glucagon, with normal GCS within 10–30 min (P = .05) and normal RBS within 10–30 min (P = .006). Conclusion: Severe hypoglycaemia is not uncommon during EMS calls. Appropriate management by EMS personals is fruitful, resulting in favourable scene outcomes and reducing the hospital transportation rate. More research should be invested in improving and structuring the prehospital management of severe hypoglycaemia. One goal is to clarify the superiority of parenteral glucose over intramuscular glucagon in the prehospital setting.


2012 ◽  
Vol 30 (27) ◽  
pp. 3368-3375 ◽  
Author(s):  
Jonathan W. Friedberg ◽  
Michelle Byrtek ◽  
Brian K. Link ◽  
Christopher Flowers ◽  
Michael Taylor ◽  
...  

PurposeThe optimal management of stage I follicular lymphoma, according to consensus guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment approaches are used despite guidelines that recommend radiation therapy (XRT).Patients and MethodsWe analyzed outcomes of patients with stage I follicular lymphoma enrolled onto the National LymphoCare database.ResultsOf 471 patients with stage I follicular lymphoma, 206 patients underwent rigorous staging as defined by both a bone marrow aspirate and biopsy and an imaging study (a computed tomography [CT] scan of the whole body, a positron emission tomography [PET]/CT scan, or both). Rigorously staged patients had superior progression-free survival (PFS) compared with nonrigorously staged patients (hazard ratio [HR], 0.63). Treatments given to rigorously staged patients were rituximab/chemotherapy (R-chemo; 28%), XRT (27%), observation (17%), systemic therapy + XRT (13%), rituximab monotherapy (12%), and other (3%). With a median follow-up of 57 months for PFS, there were 44 progression events (in 21% of patients) for rigorously staged patients. For these patients, PFS was significantly improved with either R-chemo or systemic therapy + XRT compared with patients receiving XRT alone after adjustment for histology, LDH, and the presence of B symptoms. There were no differences in overall survival.ConclusionIn this largest, prospectively enrolled group of patients with stage I follicular lymphoma, variable treatment approaches resulted in similar excellent outcomes, which challenges the paradigm that XRT should be standard for this presentation.


2012 ◽  
Vol 9 (11) ◽  
pp. S53-S60 ◽  
Author(s):  
Loretta J. Nastoupil ◽  
Rajni Sinha ◽  
Auldyn Hirschey ◽  
Christopher R. Flowers

Author(s):  
Brendan Delaney ◽  
Alex C Ford ◽  
David Forman ◽  
Paul Moayyedi ◽  
Michelle Qume

2000 ◽  
Vol 109 (3) ◽  
pp. 262-266 ◽  
Author(s):  
Alan A. Tan Lim ◽  
Antoine P. Washington ◽  
John H. Greinwald ◽  
Lorenz F. Lassen ◽  
Michael R. Holtel

Although most tympanic membrane perforations heal spontaneously, persistent perforations frequently require treatment by otolaryngologists. Initial management strategies include keeping the ear dry, ensuring aural hygiene, and using topical antibiotics. For persistent perforations, paper patching or myringoplasty may be required. Recently, agents such as hyaluronic acid and epidermal growth factor have been used to promote tympanic membrane healing. Similarly, pentoxifylline, a pharmaceutical agent with hemorrheological and antithrombotic properties, has been shown to increase perfusion and accelerate wound healing. This double-blinded prospective study attempts to examine the effect of pentoxifylline on tympanic membrane healing of 50 guinea pigs subjected to myringotomy. Serial examinations and histopathologic sectioning of the tympanic membranes revealed no significant difference in rate of healing or quality of repair between the pentoxifylline and control groups.


Sign in / Sign up

Export Citation Format

Share Document